Fig. 3: Vaccine-elicited immune serum control of SARS-CoV-2 WA1/2020 N501/D614G infection in wild-type, FcγR I KO, FcγR II KO, FcγR III KO and FcγR I/III/IV KO mice.
a, Scheme of passive transfer, virus challenge and tissue collection. b, Neutralizing antibody response against SARS-CoV-2 WA1/2020 N501Y/D614G using sera from naïve (circles) or Wuhan-1 spike protein vaccinated (squares) mice. Also shown is serum neutralizing antibody activity from recipient wild-type and FcγR I/III/IV KO mice 1 day after transfer of immune sera. c–g, Twelve-week-old male wild-type, FcγR I KO, FcγR II KO, FcγR III KO and FcγR I/III/IV KO mice were passively transferred by intraperitoneal injection 60 μl of naïve or vaccine-immune sera 1 day before intranasal challenge with 104 FFU of WA1/2020 N501Y/D614G. At 4 dpi, viral RNA and infectious virus were measured in the upper respiratory tract (nasal wash (c); nasal turbinates (d and e); or lungs (f and g). In c–e, wild-type mice only; in f and g, wild-type, FcγR I KO, FcγR II KO, FcγR III KO and FcγR I/III/IV KO mice (bars indicate mean ± standard error of the mean; in order left to right n = 5 (b); n = 18 and 11 (c); n = 18 and 11 (d); n = 18 and 11 (e); n = 18, 9, 9, 12, 10, 11, 8, 10, 11 and 11 (f); n = 18, 9, 9, 12, 10, 11, 8, 10, 11 and 11 (g) mice per group, one experiment (b), three experiments (c–g), dotted lines show limit of detection (LOD)). One-way ANOVA with Tukey’s post-test (NS, not significant; **P = 0.0068, ****P < 0.0001 (f); ***P = 0.0002, ****P < 0.0001 (g)); additional statistical comparisons are presented in Supplementary Table 3.
